Emsam Patch: The MAOI Without the Full Diet Restrictions
Last updated November 5, 2026
Key Takeaways
- Emsam is selegiline delivered through a skin patch. It's an MAOI approved for adults with major depressive disorder, and the starting and target dose is 6 mg per 24 hours.
- Because the patch bypasses the gut on the way in, the FDA label says no special diet is needed at 6 mg. At 9 mg and 12 mg, tyramine-rich foods such as aged cheese and tap beer must be avoided.
- In trials, people on Emsam had more skin reactions and insomnia than people on placebo, but rates of sexual side effects and weight gain were similar to placebo.
- Emsam can never be combined with SSRIs, SNRIs, and several other drugs. Switching from an SSRI usually means waiting at least one week, or five weeks after fluoxetine, under a prescriber's plan.
You’ve tried two or three antidepressants without enough relief. Then someone mentions an MAOI, and the first thing you hear is a list of foods you’re supposedly never allowed to eat again: aged cheese, salami, tap beer, soy sauce.
Your body uses enzymes called monoamine oxidase, or MAO, to break down mood-related chemical messengers like serotonin, norepinephrine, and dopamine. The same enzyme family lines your gut, where MAO-A breaks down tyramine, a compound in aged and fermented foods, before it can raise your blood pressure. Oral MAOIs are absorbed through that same gut. A patch delivers the drug through the skin instead, and the FDA prescribing information for Emsam explains that this route avoids extensive first-pass metabolism. Changing the route changes how the drug meets your body, with real precision.
MAOIs are among the oldest antidepressants, and they work. A meta-analysis of atypical depression trials found that MAOIs outperformed placebo and tricyclic antidepressants in depression with atypical features, such as oversleeping, increased appetite, and sensitivity to rejection. A 2013 MAOI review notes there is little doubt about their efficacy. The results are real, and the science is well established.
But for most people, the diet has been the dealbreaker, and at Siggy we think you deserve to know that one version of this class changes that tradeoff at its starting dose.
Emsam is selegiline in a once-daily skin patch, approved by the FDA in 2006 for adults with major depressive disorder. At its 6 mg starting dose, the label says no special diet is required, based on its tyramine studies. That difference comes from the route a drug takes through the body, and it rests on pharmacology.
What This Page Covers
- What Is the Emsam Patch?
- How Does a Patch Change the Diet Rules?
- How Well Does Emsam Work?
- What Are the Side Effects of Emsam?
- Which Medications Can’t Be Combined With Emsam?
- Who Might Emsam Fit, and Who Should Avoid It?
- How Siggy Fits In
- Start Your Anonymous Intake
What Is the Emsam Patch?
Emsam comes in three strengths that deliver about 6 mg, 9 mg, or 12 mg of selegiline over 24 hours. According to the label, you apply one patch every 24 hours to dry, intact skin on the upper torso, upper thigh, or outer upper arm.
The recommended starting dose and target dose is 6 mg per 24 hours. If a prescriber increases it, the label calls for steps of 3 mg no sooner than every 2 weeks, up to 12 mg. The label also notes that the trials weren’t designed to show whether higher doses work better than 6 mg, and adults 65 and older are advised to stay at 6 mg.
At antidepressant doses, selegiline blocks both forms of MAO, A and B, in the brain. That’s different from SSRIs, which work on serotonin recycling. Our MAOIs list compares Emsam with the oral options.
How Does a Patch Change the Diet Rules?
The answer is in the label’s tyramine challenge studies. In one comparison, people on Emsam 6 mg needed an average of 270 mg of tyramine to raise their systolic blood pressure by 30 points, compared with 10 mg for people on the oral MAOI tranylcypromine. A high-tyramine meal contains up to about 40 mg.
Real-world trials point the same way. Except for one study, the late-stage trial program of 2,553 patients didn’t require a special diet, and no hypertensive crises were reported. Higher doses are different: at 12 mg, some fasting volunteers reacted to as little as 25 mg of tyramine, which is why the diet returns at 9 mg and above.
Here’s how the label’s diet guidance changes by dose.
| Dose | Diet Needed | Key Notes |
|---|---|---|
| 6 mg per 24 hours | No modified diet | Starting and target dose |
| 9 mg per 24 hours | Avoid tyramine-rich foods | Start day one, continue 2 weeks after |
| 12 mg per 24 hours | Avoid tyramine-rich foods | Maximum dose |
At 9 mg and 12 mg, the label’s list of foods to avoid includes aged cheeses, air-dried or fermented meats and salami, pickled herring, tap or unpasteurized beer, fava bean pods, concentrated yeast extracts like Marmite, sauerkraut, most soy products including soy sauce and tofu, and any spoiled meat or fish. Fresh meats, processed cheese, mozzarella, and yogurt are fine. Alcohol isn’t recommended at any dose.
Know the warning signs of a hypertensive crisis, which the label describes as a severe headache at the back of the head, a pounding heart, a stiff or sore neck, nausea or vomiting, sweating, and sensitivity to light. If these appear, call 911.
How Well Does Emsam Work?
In a six-week randomized trial of 177 adult outpatients, people using the selegiline patch improved more than those on placebo across every depression measure. Participants in that study followed a tyramine-restricted diet. The label adds an 8-week trial of 265 patients using 6 mg to 12 mg that also beat placebo.
The benefit can last. In a 52-week relapse prevention trial, people who had responded to Emsam 6 mg and kept using it relapsed less often than those switched to placebo: 16.8% versus 30.7%. No hypertensive crises were reported, even without required diet restrictions.
To put the effect in everyday terms, a pooled analysis of five trials found that about 11 people needed treatment for one extra person to respond, and about 9 for one extra remission, compared with placebo. The authors called that similar to other antidepressants. One author worked for the manufacturer, and the trials were the ones submitted for approval.
What Are the Side Effects of Emsam?
Skin reactions are the main tradeoff. In the label’s pooled short-term trials, 24% of people on Emsam had a reaction where the patch sat, compared with 12% on placebo. Most were mild or moderate, and 2% stopped treatment because of them.
Here’s how other common side effects compared with placebo in those trials:
- Insomnia: 12% versus 7%.
- Diarrhea: 9% versus 7%.
- Dry mouth: 8% versus 6%.
- Rash: 4% versus 2%.
Some side effects common with other antidepressants were rare. The label reports sexual side effect rates comparable to placebo, and people on Emsam lost an average of 1.2 pounds over 6 to 8 weeks, while people on placebo gained 0.3 pounds. Dizziness when standing up deserves attention, too, since 9.8% of people on Emsam had a notable drop in blood pressure with position changes, versus 6.7% on placebo.
Keep the patch away from heat. The label warns against heating pads, electric blankets, heat lamps, saunas, hot tubs, heated waterbeds, and prolonged direct sunlight, because heat may increase how much drug your skin absorbs.
Which Medications Can’t Be Combined With Emsam?
This is the most important safety section. The label contraindicates Emsam with SSRIs, SNRIs, the tricyclics clomipramine and imipramine, the pain medicines meperidine, tramadol, methadone, and pentazocine, and the cough suppressant dextromethorphan, because together they can cause serotonin syndrome. Carbamazepine is also off-limits because it can raise selegiline levels and the risk of a hypertensive crisis.
Timing matters when switching. The label calls for about one week after stopping most of these drugs before starting Emsam, at least 5 weeks after stopping fluoxetine because it lingers in the body, and at least 2 weeks after stopping Emsam before starting any of them. Your prescriber should plan any switch.
The label also advises blood pressure monitoring if Emsam is used with buspirone, amphetamines, or cold and weight-loss products containing decongestants such as pseudoephedrine or phenylephrine. Our guide to serotonin syndrome symptoms explains what to watch for.
Who Might Emsam Fit, and Who Should Avoid It?
Emsam may be worth discussing if depression hasn’t responded well to other antidepressants, if your depression has atypical features, or if sexual side effects or weight gain made earlier medications hard to stay on. A 2024 editorial on MAOIs argued that the class is seriously underused in major depression.
Others should avoid it or use extra caution, according to the label:
- Children under 12, for whom it’s contraindicated because of hypertensive crisis risk.
- Teens 12 to 17, since a trial in 308 adolescents didn’t show benefit.
- People with pheochromocytoma, a rare adrenal tumor.
- People with a personal or family history of bipolar disorder, who should be screened first.
- People who are pregnant or breastfeeding, who need a careful risk discussion.
Like all antidepressants, Emsam carries a boxed warning about suicidal thoughts and behaviors in people under 25. If you’re on Emsam and notice worsening mood or thoughts of harming yourself, contact your prescriber right away, or call 911 or call or text 988.
How Siggy Fits In
“When side effects start, you’re on your own until the next appointment.” With a medication like Emsam, where interactions and dose changes carry real stakes, that gap matters even more.
Siggy’s licensed prescribers diagnose and treat the full range of mental health conditions, and SSRIs are one common option. Because Emsam can’t be combined with SSRIs, any move between the two needs a planned washout managed by your prescriber. If you’ve tried several antidepressants, Siggy’s free, anonymous intake lets you lay out that history, what helped, and what side effects pushed you off, with no name, email, or login. It gathers structured information and doesn’t diagnose you on its own. A licensed prescriber reviews everything before anything is prescribed, and you get a downloadable summary to share with a psychiatrist who is weighing MAOI options with you.
Siggy isn’t an emergency service. If you’re having thoughts of harming yourself, call 911 or call or text 988. This article is for education and isn’t a substitute for advice from your own prescriber. It reflects sources available as of November 2026.
Start Your Anonymous Intake
The Emsam patch keeps the established benefits of an MAOI while removing the strict diet at its starting dose, though it still demands respect for drug interactions, heat, and higher-dose food rules. For people who’ve cycled through other antidepressants, it’s a real option to raise. Our guide to treatment-resistant depression options covers where it sits among other next steps. Start your anonymous intake with Siggy to share your medication history without your name or email. It’s free, a licensed prescriber reviews your full picture before anything is prescribed, and your summary is yours to keep.
Mental healthcare should stay with you between appointments.
Siggy combines daily check-ins with clinician-supervised care so your treatment plan can respond to what is actually happening.
Start anonymously. A real doctor reviews every clinical decision. HIPAA-compliant.
Frequently Asked Questions
Do you have to follow a special diet on the Emsam patch?
Not at the starting dose. The FDA label says a modified diet isn't required at Emsam 6 mg per 24 hours. At 9 mg or 12 mg, you need to avoid tyramine-rich foods, such as aged cheeses, cured or fermented meats, tap beer, and soy sauce, starting the first day and continuing for 2 weeks after lowering the dose or stopping.
What are the most common side effects of Emsam?
The most common Emsam side effect is a skin reaction where the patch sits, reported by 24% of people in trials versus 12% on placebo. Insomnia, diarrhea, and dry mouth were also somewhat more common than with placebo. Most skin reactions were mild or moderate.
Does Emsam cause weight gain or sexual side effects?
Emsam doesn't appear to cause much weight gain or sexual dysfunction. In label data, rates of sexual side effects were comparable to placebo, and people on Emsam lost an average of 1.2 pounds over 6 to 8 weeks. A pooled analysis of five trials found no clinically relevant differences from placebo for weight or sexual function.
Can you take Emsam with an SSRI?
No, Emsam can't be combined with SSRIs, SNRIs, and several other drugs because of the risk of serotonin syndrome, which can be life-threatening. The FDA label calls for about one week after stopping most of these drugs before starting Emsam, at least 5 weeks after fluoxetine, and 2 weeks after stopping Emsam before starting them.
How well does the Emsam patch work?
Emsam works about as well as other antidepressants in trials. A pooled analysis found about 9 to 11 people needed to be treated for one extra person to respond or reach remission compared with placebo. In a 52-week relapse prevention trial, 16.8% of people who stayed on Emsam relapsed, compared with 30.7% who switched to placebo.
Can you use a heating pad with the Emsam patch?
No, the FDA label advises keeping the patch site away from direct heat, including heating pads, electric blankets, heat lamps, saunas, hot tubs, heated waterbeds, and prolonged direct sunlight. Heat may increase how much selegiline your skin absorbs.
Sources
- DailyMed. Emsam (selegiline transdermal system) Prescribing Information. Viatris Specialty LLC. U.S. National Library of Medicine.
- Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Research. 2006;141(1):89-101.
- Goldberg JF, Thase ME. Monoamine oxidase inhibitors revisited: what you should know. Journal of Clinical Psychiatry. 2013;74(2):189-191.
- Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. American Journal of Psychiatry. 2002;159(11):1869-1875.
- Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. Journal of Clinical Psychopharmacology. 2006;26(6):579-586.
- Citrome L, Goldberg JF, Portland KB. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders. 2013;151(2):409-417.
- Birkenhäger TK, Heijnen WTCJ. Monoamine oxidase inhibitors: seriously underused in the treatment of major depression. Acta Psychiatrica Scandinavica. 2024;150(6):497-499.